Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone
Acta Haematologica · 2024
DOI: 10.1159/000536650 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Haematologica, 2024. Verfasst von Michael Iarossi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belg…. Hauptthemen laut MEDLINE: Lenalidomide, Dexamethasone, von Willebrand Diseases, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Introduction
Acquired von Willebrand syndrome (AvWS) is a rare entity with approximately 700 cases described in the literature. A number of etiologies are responsible for this condition, mainly lymphoproliferative, myeloproliferative syndromes and cardiac diseases. Management is aimed at preventing and treating bleeds, as well as treating the underlying pathology. In the case of a monoclonal gammopathy, there are limited evidence and high heterogeneity only based on old case reports, resulting in poor quality recommendations. It seems essential in 2023 to take into account and offer the new anti-myeloma treatments available. Case Presentation: We describe the case of a patient with an AvWS secondary to an IgG smoldering multiple myeloma, experiencing multiple bleeding, treated successfully with daratumumab, lenalidomide, and dexamethasone, after multiple treatment failure.
Conclusion
Daratumumab, lenalidomide, and dexamethasone was demonstrated as a rapid and effective treatment for a patient with severe AvWS and multiple bleeding complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- Division of Haematology, Arlon, Brussels, Belgium.
Zitieren
APA
Iarossi, M., Vekemans, M. M., Weynants, N., & Hermans, C. (2024). Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone. Acta Haematologica. https://doi.org/10.1159/000536650
Vancouver
Iarossi M, Vekemans MM, Weynants N, Hermans C. Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone. Acta Haematologica. 2024. doi:10.1159/000536650
BibTeX
@article{Iarossi2024,
author = {Iarossi, Michael and Vekemans, Marie-Christiane Madeleine and Weynants, Nicolas and Hermans, Cedric},
title = {Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000536650}
}
EUVIMED